The analyst rating for WUXI BIO (02269.HK) was elevated to "Buy" by Nomura due to a positive profit alert projecting significant revenue growth of 16.7% YoY for 2025, which is slightly above market consensus. Additionally, improvements in gross margin and net profit predictions, both exceeding market expectations, contributed to the positive outlook. The anticipated strong performance of its subsidiary, WUXI XDC, was also highlighted as a key factor in driving revenue growth. Consequently, Nomura raised its target price from $37.36 to $50.54.
